E. de Nobel

412 total citations
10 papers, 310 citations indexed

About

E. de Nobel is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Nephrology. According to data from OpenAlex, E. de Nobel has authored 10 papers receiving a total of 310 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Cardiology and Cardiovascular Medicine and 3 papers in Nephrology. Recurrent topics in E. de Nobel's work include Blood Pressure and Hypertension Studies (4 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers) and Chronic Kidney Disease and Diabetes (3 papers). E. de Nobel is often cited by papers focused on Blood Pressure and Hypertension Studies (4 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers) and Chronic Kidney Disease and Diabetes (3 papers). E. de Nobel collaborates with scholars based in Netherlands. E. de Nobel's co-authors include L.D. Elving, A. van ‘t Laar, Jack F.M. Wetzels, Merel Jansen, Chris van Weel, Jo H. M. Berden, J. A. J. M. Bakkeren, Martha T. van der Beek, Henk J.J. van Lier and Guy E.H.M. Rutten and has published in prestigious journals such as Diabetes, Diabetologia and Clinical Chemistry.

In The Last Decade

E. de Nobel

10 papers receiving 291 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. de Nobel Netherlands	8	165	88	81	34	28	10	310
Miriam Pecis Brazil	11	93 0.6×	77 0.9×	156 1.9×	9 0.3×	32 1.1×	16	336
Mohammad A. Siddiqui India	8	146 0.9×	85 1.0×	199 2.5×	14 0.4×	15 0.5×	9	345
James Walker United Kingdom	6	107 0.6×	73 0.8×	56 0.7×	14 0.4×	16 0.6×	14	420
Winston Crasto United Kingdom	8	201 1.2×	62 0.7×	24 0.3×	34 1.0×	45 1.6×	18	318
Janne Kytö Finland	7	109 0.7×	27 0.3×	51 0.6×	20 0.6×	11 0.4×	10	244
Mai Yanagi Japan	12	54 0.3×	106 1.2×	190 2.3×	19 0.6×	35 1.3×	25	338
Cesar Y. Cardona United States	6	243 1.5×	108 1.2×	32 0.4×	31 0.9×	11 0.4×	8	376
Vida Sheikh Iran	11	51 0.3×	48 0.5×	33 0.4×	26 0.8×	26 0.9×	23	326
M. Pfeifer Germany	6	256 1.6×	42 0.5×	55 0.7×	19 0.6×	65 2.3×	10	391
Xinlei Miao China	7	139 0.8×	30 0.3×	142 1.8×	13 0.4×	42 1.5×	19	280

Countries citing papers authored by E. de Nobel

Since Specialization

Citations

This map shows the geographic impact of E. de Nobel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. de Nobel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. de Nobel more than expected).

Fields of papers citing papers by E. de Nobel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. de Nobel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. de Nobel. The network helps show where E. de Nobel may publish in the future.

Co-authorship network of co-authors of E. de Nobel

This figure shows the co-authorship network connecting the top 25 collaborators of E. de Nobel. A scholar is included among the top collaborators of E. de Nobel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. de Nobel. E. de Nobel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Elving, L.D., Jack F.M. Wetzels, Henk J.J. van Lier, E. de Nobel, & Jo H. M. Berden. (1994). Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia. 37(6). 604–609. 40 indexed citations

Wetzels, Jack F.M., et al.. (1994). Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Diabetologia. 37(6). 604–609. 3 indexed citations

Nobel, E. de, et al.. (1993). Diabetes and its Long-term Complications in General Practice: a Survey in a Well-defined Population. Family Practice. 10(2). 169–172. 38 indexed citations

Nobel, E. de, et al.. (1992). Screening for Diabetic Retinopathy by General Practitioners. Scandinavian Journal of Primary Health Care. 10(4). 306–309. 17 indexed citations

Elving, L.D., Jack F.M. Wetzels, E. de Nobel, Andries J. Hoitsma, & Jo H. M. Berden. (1992). Captopril Acutely Lowers Albuminuria in Normotensive Patients With Diabetic Nephropathy. American Journal of Kidney Diseases. 20(6). 559–563. 22 indexed citations

Elving, L.D., J F M Wetzels, E. de Nobel, & J. H. M. Berden. (1991). Erythrocyte sodium-lithium countertransport is not different in Type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia. 34(2). 126–128. 29 indexed citations

Rutten, Guy E.H.M., et al.. (1990). Feasibility and Effects of a Diabetes Type II Protocol with Blood Glucose Self-Monitoring in General Practice. Family Practice. 7(4). 273–278. 51 indexed citations

Elving, L.D., et al.. (1989). Screening for microalbuminuria in patients with diabetes mellitus: frozen storage of urine samples decreases their albumin content.. Clinical Chemistry. 35(2). 308–310. 72 indexed citations

Elving, L.D., E. de Nobel, Henk J.J. van Lier, & Th. Thien. (1989). A Comparison of the Hypotensive Effects of Captopril and Atenolol in the Treatment of Hypertension in Diabetic Patients. The Journal of Clinical Pharmacology. 29(4). 316–320. 5 indexed citations

10.

Nobel, E. de & A. van ‘t Laar. (1978). The Size of the Loading Dose as an Important Determinant of the Results of the Oral Glucose Tolerance Test: A Study in Subjects with Slightly Impaired Glucose Tolerance. Diabetes. 27(1). 42–48. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact